Last reviewed · How we verify
GB491+ Fulvestrant
GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells.
GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells. Used for Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant).
At a glance
| Generic name | GB491+ Fulvestrant |
|---|---|
| Also known as | test drug + Fulvestrant |
| Sponsor | Genor Biopharma Co., Ltd. |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GB491 is a novel SERD that enhances the activity of fulvestrant, a known estrogen receptor antagonist and degrader. The combination targets estrogen receptor-positive breast cancer by promoting receptor degradation and preventing estrogen-driven proliferation. This dual mechanism aims to overcome resistance to standard endocrine therapies.
Approved indications
- Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant)
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Arthralgia
- Vaginal bleeding/discharge
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |